SCHEMBL5116467

SCHEMBL5116467

Cc1oc(C2CCCCC2)nc1CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.46
PPARA Q07869 5/20 0.46
KDM4E B2RXH2 1/20 0.46
PPARD Q03181 1/20 0.45
S1PR1 P21453 1/20 0.36
S1PR5 Q9H228 1/20 0.36
ADCY1 Q08828 4/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 1/20 0.34
ADCY8 P40145 1/20 0.34
DGAT2 Q96PD7 1/20 0.34
NTRK1 P04629 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10810604 1.00 PPARG (0.46) PPARGPPARAKDM4EPPARDS1PR1
SCHEMBL10807845 0.98 KDM4E (0.47) PPARGPPARAKDM4EPPARDS1PR1
SCHEMBL15637053 0.92 KDM4E (0.49) PPARGPPARAKDM4EPPARDHPGD
SCHEMBL10813251 0.82 ADCY1 (0.38) PPARGPPARAPPARDS1PR1S1PR5
SCHEMBL9097721 0.81 PPARG (0.42) PPARGPPARAPPARDADCY1CYP2C19
SCHEMBL10812386 0.80 PPARG (0.37) PPARGPPARAPPARDS1PR1ADCY1
SCHEMBL10808564 0.79 KDM4E (0.44) PPARGPPARAKDM4EPPARDNPSR1
SCHEMBL10810549 0.79 PPARG (0.40) PPARGPPARAPPARDADCY1CYP2C19
SCHEMBL4484815 0.78 PPARG (0.45) PPARGPPARAPPARDADCY1CYP2C19
SCHEMBL5124410 0.78 PPARG (0.51) PPARGPPARAKDM4EPPARDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0096890-B1 OXAZOLEACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING SAID DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 1987-11-25 EP claimed
US-4602027-A HYPOGLYCEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-07-22 US claimed
EP-0096890-A2 Oxazoleacetic acid derivatives, process for their production and compositions containing said derivatives Takeda Chemical Industries, Ltd. (JP) 1983-12-28 EP claimed
CN-1711084-B Substituted 4-alkoxyoxazol derivatives as PPAR agonists HOFFMANN LA ROCHE 2010-04-28 CN disclosed
US-7345070-B2 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ELI LILLY AND COMPANY (US) 2008-03-18 US disclosed
EP-1572203-B1 SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS HOFFMANN LA ROCHE (CH) 2007-11-07 EP disclosed
EP-1313716-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-05-02 EP disclosed
US-7109225-B2 Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents HOFMANN-LA ROCHE INC. (US) 2006-09-19 US disclosed
CN-1711084-A Substituted 4-alkoxyoxazol derivatives as PPAR agonists HOFFMANN LA ROCHE (CH) 2005-12-21 CN disclosed
US-20050245584-A1 Peroxisome proliferator activated receptor agonists BROOKS DAWN A 2005-11-03 US disclosed
EP-1572203-A1 SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-09-14 EP disclosed
WO-2002016331-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed
US-5498621-A Oxazolidinedione hypoglycemic agents PFIZER INC. (US) 1996-03-12 US disclosed
EP-0428312-B1 Oxazolidinedione hypoglycemic agents PFIZER (US) 1994-12-28 EP disclosed
WO-1991007107-A1 OXAZOLIDINEDIONE HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1991-05-30 WO disclosed
EP-0428312-A2 Oxazolidinedione hypoglycemic agents PFIZER INC. (US) 1991-05-22 EP disclosed
EP-0096890-B1 OXAZOLEACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING SAID DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 1987-11-25 EP disclosed
EP-0124384-B1 DERIVATIVES OF ORTHOCONDENSED PYRROLE USEFUL FOR THE PREPARATION OF MEDICINES AND THEIR PREPARATION RHONE-POULENC SANTE (FR) 1987-08-05 EP disclosed
US-4602027-A HYPOGLYCEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-07-22 US disclosed
EP-0096890-A2 Oxazoleacetic acid derivatives, process for their production and compositions containing said derivatives Takeda Chemical Industries, Ltd. (JP) 1983-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245584-A1 Peroxisome proliferator activated receptor agonists PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885KDM4E 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.